- Record: found
- Abstract: found
- Article: not found
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Masanori Noguchi
1 ,
Fukuko Moriya ,
Shigetaka Suekane ,
Kei Matsuoka ,
Gaku Arai ,
Satoko Matsueda ,
Tetsuro Sasada ,
Akira Yamada ,
Kyogo Itoh
Jun 01 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Docetaxel-based chemotherapy (DBC) showed limited clinical efficacy for castration-resistant prostate cancer (CRPC) patients. To explore cancer vaccine as a new treatment modality, we conducted a phase II study of personalized peptide vaccine (PPV) for DBC-resistant CRPC patients.